Reunion Neuroscience Inc. (TSE:REUN – Get Free Report) shares dropped 2.7% during mid-day trading on Monday . The stock traded as low as C$1.41 and last traded at C$1.42. Approximately 339 shares changed hands during trading, a decline of 97% from the average daily volume of 12,447 shares. The stock had previously closed at C$1.46.
Reunion Neuroscience Price Performance
The stock has a market capitalization of C$16.64 million, a P/E ratio of -0.43 and a beta of 4.20. The stock’s 50-day moving average price is C$1.42.
About Reunion Neuroscience
Reunion Neuroscience Inc, a clinical-stage biopharmaceutical company, develops therapeutic solutions for mental health conditions in North America. The company's lead asset includes RE104, a clinical-stage serotonergic psychedelic therapeutic product for antidepressant applications. It is also developing the RE200 series, which comprises molecules that are structurally designed to be similar to classical psychedelics with selective potency at the target serotonin 2A receptor (5HT2A) for potential chronic treatment in various patient populations and indications.
Read More
- Five stocks we like better than Reunion Neuroscience
- Stock Market Sectors: What Are They and How Many Are There?
- 2 Chip Stocks Benefitting from OpenAI’s Chip Strategy Expansion
- The How And Why of Investing in Oil Stocks
- Monday.com’s Manic Price Pullback Is a Signal to Buy
- How to Use High Beta Stocks to Maximize Your Investing Profits
- 3 “Made in America” Stocks to Benefit From the Trump Presidency
Receive News & Ratings for Reunion Neuroscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reunion Neuroscience and related companies with MarketBeat.com's FREE daily email newsletter.
